Ibandronic acid/zoledronic acid
- PDF / 169,789 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 93 Downloads / 258 Views
1 S
Impending fracture, atypical femur fracture and nonunion of fracture: 5 case reports In a retrospective study involving 485 patients, who underwent ulnar shortening osteotomy between March 2008 and September 2017, five patients [including two women; sexes of the remaining patients not stated] aged 51–62 years, were described, who experienced impending fractures (3 patients) or atypical femur fractures (2 patients) following treatment with zoledronic acid or ibandronic acid. All patients additionally experienced nonunion of fractures secondary to bisphosphonate therapy with zoledronic acid or ibandronic acid [dosages not stated; times to reactions onsets not clearly stated]. The five patients, who had been receiving IV zoledronic acid [Zolendronate; 4 patients] or IV ibandronic acid [Ibandronate; 1 patient] for 62–75 months for breast cancer, exhibited nonunion following ulnar shortening osteotomy. Four patients exhibited oligotrophic nonunion, while the remaining patient exhibited atrophic nonunion. Also, three patients exhibited suspicious lesions on their femurs (impending fractures), while two patients experienced atypical femur fractures. Therefore, osteosynthesis was performed with cancellous iliac bone graft for all patients, and union was achieved. The plates were not removed for at least 2 years post surgery. The two patients, who experienced atypical femur fractures, were treated with intramedullary nailing [not all outcomes stated]. Cha SM, et al. Inevitable nonunion after ulnar shortening osteotomy in patients with ulnar impaction syndrome and breast cancer under bisphosphonate treatment. Archives of 803508137 Orthopaedic and Trauma Surgery 140: 1567-1574, No. 10, 2020. Available from: URL: http://doi.org/10.1007/s00402-020-03570-9
0114-9954/20/1826-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 17 Oct 2020 No. 1826
Data Loading...
